You just read:

Keryx Biopharmaceuticals Announces Zerenex™ (ferric citrate) Meets Primary and All Key Secondary Endpoints in Phase 3 Long-Term Study as a Treatment for Hyperphosphatemia in End-Stage Renal Disease Patients on Dialysis

News provided by

Keryx Biopharmaceuticals, Inc.

Jan 28, 2013, 07:00 EST